Table 2. Cancer Recurrence and Survival.
| Variable | No. (%) | Hazard Ratioa (90% CI) | |
|---|---|---|---|
| Trastuzumab for 9 wk (n = 1085) |
Trastuzumab for 51 wk (n = 1089) |
||
| Any recurrence or deathb | 140 (13) | 105 (10) | 1.39 (1.12-1.72) |
| Distant recurrence | 73 (7) | 61 (6) | 1.24 (0.93-1.65) |
| Locoregional recurrence | 17 (2) | 13 (1) | 1.35 (0.74-2.48) |
| Contralateral breast cancer | 15 (1) | 7 (1) | 2.24 (1.05-4.75) |
| Second cancer | 27 (3) | 24 (2) | 1.16 (0.73-1.84) |
| Death without cancer | 14 (1)c | 5 (0) | 2.88 (1.22-6.78) |
| Death from any cause | 58 (5) | 44 (4) | 1.36 (0.98-1.89) |
| Death from breast cancer | 34 (3) | 33 (3) | 1.06 (0.71-1.59) |
| Death from other caused | 24 (2) | 11 (1) | 2.24 (1.23-4.08) |
a
Calculated with an unadjusted Cox proportional hazards model.
b
Six patients in the 9-week group and 5 patients in the 1-y group had 2 disease-free survival events.
c
The cause of death was unknown in 3 cases.
d
Eleven patients died of second cancer, 5 of infection, 2 of a cardiac cause, 3 of other causes, and 3 of an unknown cause in the 9-week group; in the 1-year group, 6 died of second cancer, 2 of infection, 1 of a cardiac cause, and 2 of other causes.